JDRF Chair Premier Panel at 2021 Advanced Technologies & Treatments for Diabetes Conference Featuring Provention Bio, ViaCyte and vTv Therapeutics
June 2, 2021, New York— JDRF, the leading global funder of type 1 diabetes (T1D) research, is set to host a panel and live Q&A session at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) titled Moving Therapies Across the Type 1 Diabetes Disease Continuum and Across the Pipeline: The Critical Role in Public-Private Partnerships.
“JDRF is excited to host this session at one of the premier global conferences dedicated to technology and the treatment of diabetes,” said Sanjoy Dutta, Ph.D., JDRF Vice President of Research. “We have gathered some of the industry’s top experts and organizations together to provide a detailed insight into breakthrough T1D therapies.”
Taking place on Thursday, June 3 at 17:15 – 18:45 CEST, the panel led by Dutta will address leading topics related to T1D research, treatment and cures, featuring presentations from Dr. Andrew Cagle, MD, FAAP, Provention Bio, Dr. Kevin D’Amour, Ph.D., Chief Scientific Officer, ViaCyte, and Dr. Carmen Valcarce, Ph.D., Chief Scientific Officer, vTv Therapeutics.
Provention Bio: Dr. Andrew Cagle will discuss experimental approaches to T1D interception and prevention, including the importance of T1D screening and staging for research and the development of targeted treatments. He also will provide an overview of Provention Bio’s development programs underway focused on the entire T1D disease continuum and review the biology and data behind why a coxsackievirus B vaccine is an appropriate target to potentially prevent T1D.
ViaCyte: Dr. D’Amour will provide an update on ViaCyte’s progress toward developing a functional cure for T1D. ViaCyte is currently in the clinic with two ongoing Phase 2 studies of its stem cell derived islet replacement therapy for T1D. Through its therapy, ViaCyte aims to give people with diabetes freedom from their disease by improving their health, glucose levels and independence from the burden of continuous management. The ability of the cells to produce both insulin and glucagon is designed to help modulate both the highs and lows, providing better control of blood glucose through a cell therapy with the potential to offer long-term treatment and improved patient outcomes.
vTv Therapeutics: In her segment titled “Future of Adjunctive Therapy: Simplifying the Treatment of T1D through GK Activation,” vTv’s Chief Scientific Officer, Carmen Valcarce, Ph.D., will discuss the future of adjunctive therapies to insulin, specifically with a novel, liver selective, Glucokinase activator. Dr. Valcarce will review the recently published phase 2 study results in T1D where treatment with TTP399, which recently received Breakthrough Therapy designation, resulted in a statistically significant improvement in HbA1c relative to placebo and a clinically meaningful decrease in the frequency of severe and symptomatic hypoglycemia, all without increasing risk of diabetic ketoacidosis.
JDRF: During this session JDRF will address the unmet needs across the T1D disease continuum from individuals at risk to those living with the disease for decades and opportunities to move therapies across the development pipeline. Sanjoy Dutta, Ph.D. will provide an overview of the JDRF research strategy to prioritize partnerships that will ultimately lead to better outcomes in people living with T1D.
JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).
About Provention Bio
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company’s pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation. ViaCyte has the opportunity to use these technologies to address critical human diseases and disorders that can potentially be treated by replacing lost or malfunctioning cells or proteins. The company’s first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand the company’s efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. For more information, please visit www.viacyte.com and connect with ViaCyte on Twitter, Facebook, and LinkedIn.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes (T1D) and psoriasis. vTv’s investigational drug candidate, TTP399, received Breakthrough Therapy designation for the treatment of T1D and pivotal trials are being planned.
vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.
Glenn Silver, Lazar-FINN Partners,
Lori Rosen, Lori Rosen Communications